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Abstract: 
 
Background: Historically, Holder pasteurization has been used to pasteurize donor human milk 
available in a hospital setting. There is extensive research that provides an overview of the 
impact of Holder pasteurization on bioactive components of human milk. A shelf-stable (SS) 
human milk product, created using retort processing, recently became available; however, to our 
knowledge, little has been published about the effect of retort processing on human milk. 
Objective: We aimed to assess the ability of retort processing to eliminate bacteria and to 
quantify the difference in lysozyme and secretory immunoglobulin A (sIgA) activity between 
Holder pasteurized (HP) and SS human milk. Methods: Milk samples from 60 mothers were 
pooled. From this pool, 36 samples were taken: 12 samples were kept raw, 12 samples were HP, 
and 12 samples were retort processed to create an SS product. All samples were analyzed for 
total aerobic bacteria, coliform bacteria, Bacillus cereus, sIgA activity, and lysozyme activity. 
Raw samples served as the control. Results: One raw sample and 3 HP samples contained B. 
cereus at the time of culture. There were no detectable bacteria in SS samples at the time of 
culture. Raw samples had significantly greater lysozyme and sIgA activity than HP and SS 
samples (P < 0.0001). HP samples retained significantly more lysozyme and sIgA activity (54% 
and 87%, respectively) than SS samples (0% and 11%, respectively). Conclusions: Human milk 
processed using Holder pasteurization should continue to be screened for the presence of B. 
cereus. Clinicians should be aware of the differences in the retention of lysozyme and sIgA 
activity in HP and SS products when making feeding decisions for medically fragile or 
immunocompromised infants to ensure that patients are receiving the maximum immune 
protection. 
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Abstract
Background: Historically, Holder pasteurization has been used to pasteurize donor human milk
available in a hospital setting. There is extensive research that provides an overview of the impact
of Holder pasteurization on bioactive components of human milk. A shelf-stable (SS) human milk
product, created using retort processing, recently became available; however, to our knowledge,
little has been published about the effect of retort processing on human milk.
Objective:We aimed to assess the ability of retort processing to eliminate bacteria and to quantify
the difference in lysozyme and secretory immunoglobulin A (sIgA) activity between Holder
pasteurized (HP) and SS human milk.
Methods: Milk samples from 60 mothers were pooled. From this pool, 36 samples were taken: 12
samples were kept raw, 12 samples were HP, and 12 samples were retort processed to create an
SS product. All samples were analyzed for total aerobic bacteria, coliform bacteria, Bacillus
cereus, sIgA activity, and lysozyme activity. Raw samples served as the control.
Results: One raw sample and 3 HP samples contained B. cereus at the time of culture. There were
no detectable bacteria in SS samples at the time of culture. Raw samples had significantly greater
lysozyme and sIgA activity than HP and SS samples (P, 0.0001). HP samples retained significantly
more lysozyme and sIgA activity (54% and 87%, respectively) than SS samples (0% and 11%,
respectively).
Conclusions: Human milk processed using Holder pasteurization should continue to be screened
for the presence of B. cereus. Clinicians should be aware of the differences in the retention of
lysozyme and sIgA activity in HP and SS products when making feeding decisions for medically
fragile or immunocompromised infants to ensure that patients are receiving the maximum
immune protection. Curr Dev Nutr 2017;1:e001438.
Introduction
The nutritional requirements of premature infants can be difficult to meet and their
mother’s own milk (MOM) is the preferred food source after premature delivery, owing
to the increased nutritional value of human milk (1, 2). Human milk contains bioactive
components that help to protect the medically fragile infant from the development of
complications such as sepsis, retinopathy of prematurity, and necrotizing enterocolitis
(3–5). The protective benefits of human milk are maximized when an exclusively hu-
man milk diet is maintained, decreasing retinopathy rates by.20% and necrotizing en-
terocolitis rates by 12–14% (4–6). When babies are born prematurely, the mother is at
an increased risk of delayed onset of lactogenesis II or low milk volume (7–9). Donor
human milk (DHM) can be used to maintain an exclusively human milk diet until
the mother’s milk supply is established (10, 11).
Historically, the Human Milk Banking Association of North America (HMBANA) has
been the provider of DHM in medical settings. To protect infants from potentially
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pathogenic bacteria, all donated milk is pasteurized and screened
for bacteria. Holder pasteurization (62.58C for 30 min) is the stan-
dard pasteurization method for HMBANA milk banks and has
been shown to eliminate all pathogenic bacteria except Bacillus ce-
reus (12). In addition, Holder pasteurization retains many bioac-
tive compounds in human milk, including 40–75% of lysozyme
function and 50–100% of secretory IgA (sIgA) function (12, 13).
Recently, a shelf-stable (SS) DHM product developed with retort
processing became available for use in a neonatal intensive care unit
(NICU) setting in the United States. Retort processing differs from
Holder and high-temperature, short-time pasteurization, which are
currently themost widely used and researched thermal pasteurization
methods, in the temperatures utilized, time of heat exposure, pressure
utilized, and shelf life of the product (14).
SS DHM may be an option for smaller facilities lacking storage
and refrigeration space. However, to our knowledge, there is cur-
rently only one published study that investigates the effect of retort
processing on bioactive components of human milk (15). Results
from the study by Meredith-Dennis et al. (15) indicate destruction
of bioactive components in retort processed milk compared with
Holder pasteurized (HP) milk. Unfortunately, only 3 samples
were analyzed per treatment group and all samples originated
from different donor pools. Because concentrations of bioactive
components in human milk can vary widely between mothers
(16), it is difficult to draw definitive conclusions from the results
of the study by Meredith-Dennis et al. (15).
Characterizing the bioactivity in different forms of DHM will
allow informed choices regarding nutritional interventions for
premature infants. Lysozyme and sIgA were chosen for analysis
because of their roles in immune protection in the gastrointestinal
tract. Lysozyme degrades the outer cell wall of gram-positive bac-
teria (17) and contributes to destruction of gram-negative bacteria in
vitro (18). sIgA is synthesized by the mother’s immune system in re-
sponse to environmental cues and binds microbes in the infant’s
gastrointestinal tract to prevent their passage into other tissues (19).
Fragile infants who receive MOM or DHM with active sIgA
and lysozyme have increased protection against pathogens within
their environment (1, 20). Holder pasteurization and retort pro-
cessing may yield DHMwith different bioactive profiles. Research
has shown that as the heat of the treatment increases, the destruc-
tion of bioactive components in human milk also increases (21).
This study assesses the ability of retort processing to eliminate
bacteria and quantifies the difference in lysozyme and sIgA activ-
ity between HP and SS human milk.
Methods
The North Carolina State University Institutional Review Board
granted ethical approval for this study. Raw human milk was ob-
tained from 60 approved donors through WakeMed Mothers’
Milk Bank (Cary, NC). When women donate to WakeMedMothers’
Milk Bank, they consent that their milk may be used for research
studies if it is unable to be used for medical purposes. One sample
from each mother was obtained and used to create a pool of raw hu-
man milk totaling 260 ounces (7.69 liters). The samples were pooled
in theWakeMedMothers’Milk Bank by a trained technician using a
standard pooling protocol. Each individual sample was thawed in
the refrigerator prior to pooling. Proper personal protective equip-
ment was worn during handling of the milk per HMBANA guide-
lines. When samples were adequately thawed, they were moved
under a sanitized laminar flow hood to prevent contamination dur-
ing the pooling process. Tominimize fat separation and ensure max-
imum transfer of the contents, samples were removed from the
original milk storage containers and transferred into 4000-mL
beakers before they were completely thawed. During thawing, tem-
peratures were maintained #48C to discourage additional bacterial
growth. When all individual samples were completely thawed, they
were combined into multiple wide-mouth Erlenmeyer flasks and
mixed using a pour-down method 6 times (Figure 1A). Once mixed,
samples were swirled gently for homogenization and were strained
prior to bottling (Figure 1B).
Twenty-four 3-ounce (88.7 mL) samples were taken from the
pooled milk and stored in Orthofix AXifeed 100-mL bottles (pro-
duct no. 022001010; Nolato Jaycare Limited). Twelve samples re-
ceived no further treatment (referred to hereafter as raw human
milk samples) and 12 samples were processed usingHolder pasteur-
ization (62.58C for 30 min) in an ACE Intermed Special Feed Pas-
teurizer (model HMP2070-40HCUL) at the WakeMed Mothers’
Milk Bank.
All milk was kept refrigerated whenever it was not being pooled or
processed. The remaining pooled milk was transferred into 2000-mL
Erlenmeyer flasks and put on ice for transport to North Carolina State
University (,30 min) for bottling and retort processing to create a SS
product. Upon arrival, the remaining pooled milk was swirled gently
for homogenization (Figure 1B) and was then poured into twelve 10-
ounce (295.7 mL) aluminum cans, leaving 3–6 mm of air space at the
top. Cans were sealed using a can sealer (Dixie Canner Company) and
were retort processed to create a SS product (1218C, 20 psi for 5 min)
using a full water immersion retort processer (PR-I900; Stock Amer-
ica Inc.). After all processing was completed, all samples were ali-
quoted and stored at 2808C until analysis. Note that all milk only
underwent 1 freeze-thawcycle tomimic the freeze-thawcycle that oc-
curs in aHMBANAmilk bank. Each samplewas analyzed for bacterial
content (per standard protocols at the WakeMed Pathology Labora-
tory), sIgA activity, and lysozyme activity, as described below.
Bacterial screening
Bacterial analysis was completed at the WakeMed Pathology Labo-
ratory in accordance with the HMBANA guidelines for quantitative
bacterial analysis for mothers’milk. HP and SS samples underwent a
full postprocessing culture to identify any present bacteria. Raw hu-
man milk samples were screened for the presence of B. cereus, Esch-
erichia coli, general appearance of Enterococcus, gram-negative rods,
yeast, and Staphylococcus aureus. Because of the large variety of bac-
teria potentially present in raw human milk samples (22), we chose
to only screen for bacteria that may be of concern in a DHM setting,
specifically with use in the NICU.
sIgA activity
sIgA activity in our samples was measured using a modified indirect
ELISA. Briefly, flat-bottom, high-binding, 96-well plates were
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incubated for 12–18 h with an E. coli antigen. After completion of
the incubation period, plates were washed 3 times with PBS plus
0.05% Tween 20 (PBST). Human milk samples and human IgA
from colostrum standards (I-2636; Sigma-Aldrich) were then
plated in triplicate and incubated for 3 h at room temperature.
Plates were washed with PBST after the incubation period and
were then loaded with HRP anti-human IgA (A-0295; Sigma-
Aldrich) and incubated for 1 h at room temperature. Afterward,
plates were washed a final time with PBST. The substrate solution
(20 mL of 0.05 M citrate buffer, 0.1 mL of 3% hydrogen peroxide,
and 0.5mL of 40mM2,29-azinodi-3-ethylbenzothiazoline-6-sulfonic
acid) was then added and immediately read on a microplate reader
(Multiskan EX; Thermo Electron Corp.) at 405 nm at time 0 and
every 2 min for 20 min. To determine sIgA activity, the changes
in absorption over time were graphed and a regression line was
computed for each of the samples and the standards. The samples
were then compared with the IgA standards to determine activity.
CVs for triplicates were between 1% and 6%.
Lysozyme activity
Lysozyme activity was measured using the change in turbidity of a
microbial suspension of Micrococcus lysodeikticus, a method devel-
oped and adapted for use in a 96-well plate (23, 24). Briefly, 25 mL
of each humanmilk sample was plated in triplicate in a 96-well plate
(1:20 diluted raw human milk samples, 1:10 diluted HP samples, and
undiluted SS samples), and 200 mL of the Micrococcus lysodeikticus
suspension (M3770; Sigma-Aldrich) (reading ;1.00 at 450 nm on a
2600 Gilford spectrophotometer) was added to each well using a
multichannel pipette. The 96-well plate was read on a microplate
reader (Multiskan EX; Thermo Electron Corp.) at 450 nm every
30 s for 6 min.R2 values were calculated to ensure appropriate func-
tion of the assay and the CV was used to determine reliability. CVs
FIGURE 1 (A) WakeMed Mothers’ Milk Bank standard mixing protocol for combination of 4 flasks of human milk. (B) WakeMed Mothers’
Milk Bank standard homogenization, straining, and bottling protocol for human milk.
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for triplicates were between 5% and 7%. Lysozyme activity was then
calculated using the following equation:
LysozymeðU=mLÞ ¼ ½mean change in absorption=ð0:001
3 volume of sample inmLÞ
3 dilution factor of milk samples
Statistical analysis
Human milk samples from each treatment group were analyzed in
triplicate for analysis of lysozyme and sIgA activity. A statistical com-
parison of lysozyme activity and sIgA activity between rawmilk, HP
milk, and SS milk was done with one-factor ANOVA. Differences
between means 6 SDs were tested for significance (a = 0.05) with
Tukey’s honest significant difference test.
Results
Bacteria
Raw milk samples were screened for the presence of B. cereus, E.
coli, general appearance of Enterococcus, gram-negative rods, yeast,
S. aureus, and Pseudomonas species. All raw milk samples contained
Enterococcus species, gram-negative rods, yeast, and Pseudomonas
species. One raw milk sample contained B. cereus. These results
were typical of raw human milk and served as a control for HP sam-
ples and SS samples (Table 1).
HP samples and SS samples went through a complete postpro-
cessing screen to characterize any bacteria present. Three samples
of HPmilk had growth of B. cereus. No other growth was observed
in HP milk. SS samples had no bacterial growth (Table 1).
sIgA activity
sIgA was measured in all samples, using raw humanmilk samples as
the control. The analysis showed a mean of 1.04 6 0.09 mg active
sIgA/mL in raw human milk samples and was significantly more
than HP and SS human milk from the same pool (0.90 6 0.03 and
0.116 0.07 mg active sIgA/mL, respectively, P , 0.0001; Figure 2).
Lysozyme activity
Lysozyme activity was measured in all samples, using raw human
milk samples as the control. Raw humanmilk samples had a mean ly-
sozyme activity of 79696 1394U/mL,whichwas significantly greater
(P, 0.001) than both HP lysozyme activity (42696 963 U/mL) and
SS lysozyme activity (no activity detectible; Figure 3).
Discussion
In the NICU setting, it is imperative to scrutinize nutritional inter-
ventions to avoid expensive, life-threatening complications (6, 25).
With emerging options for human milk–based feeding, evidence
on the full spectrum of feeding choices is needed in order to inform
best practice. MOM is the recommended feeding choice for prema-
ture infants (1, 2). Whenever possible, breastfeeding should be sup-
ported and encouraged if the mother’s goal is to breastfeed. When
the mother faces obstacles in establishing an adequate milk supply
for the infant(s), DHMprovides a mechanism for the medically frag-
ile infant to maintain exclusively humanmilk feedings. The effects of
various human milk processing methods on nutrient and bioactive
retention may impact health outcomes and are an important area
of future research.
Compared with raw human milk, our results show that human
milk processed via Holder pasteurization retains more sIgA activ-
ity and lysozyme activity (87% and 54%, respectively) than SS hu-
man milk (11% and 0%, respectively). Compared with raw human
milk, the reduction of activity observed in HP human milk is con-
sistent with ranges reported in the literature (13, 14). Because our
study looked specifically at biological activity rather than the con-
centration of lysozyme and sIgA, there was no published literature
to use as a reference for expected values or ranges. Meredith-
Dennis et al. (15) found lower concentrations of IgA and no differ-
ence in lysozyme concentrations when comparing Holder and re-
tort processed milk. These results may or may not be in agreement
with our findings, because the measured protein concentration
can remain the same even when there is a loss of biological activity
owing to partial denaturation. In addition, it was a cross-sectional
study with different donor pools represented in each treatment
group (15); therefore, differences in milk composition cannot be
specifically attributed to processing effects.
In our study, Holder pasteurization eliminated all bacteria ex-
cept B. cereus. It is understood that Holder pasteurization does not
kill B. cereus and causes B. cereus spores to sporulate during heat-
ing (12, 26). HMBANA milk banks have chosen to continue using
this method and to screen for and discard any batches that are
positive for B. cereus postprocessing to preserve the value of the
TABLE 1 Results of bacterial analysis in raw, Holder pasteurized, and shelf-stable human milk1
Sample
Samples containing bacteria
Pseudomonas
species
Gram-
negative
rods
Enterococcus
species Yeast
Bacillus
cereus
Escherichia
coli
Staphylococcus
aureus
Raw (unpasteurized) 12 (100) 12 (100) 12 (100) 12 (100) 1 (8.3) 0 (0) 0 (0)
Holder pasteurized
(62.58C for 30 min)
0 (0) 0 (0) 0 (0) 0 (0) 3 (25) 0 (0) 0 (0)
Shelf-stable, retort
processed
(1218C, 20 psi for 5 min)
0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
1Values are n (%).
CURRENT DEVELOPMENTS IN NUTRITION
4 Lima et al.
D
ow
nloaded from
 https://academ
ic.oup.com
/cdn/article/1/8/e001438/4735239 by U
niversity of N
orth C
arolina at G
reensboro user on 01 Septem
ber 2020
milk. Retort processing used to create the SS product eliminated
all bacteria. Our study provides evidence that retort processing
is effective at eliminating all bacteria from human milk, whereas
HP DHMmust continue to be screened for B. cereus pre- and post-
processing to ensure its safety for consumption by medically fragile
infants. The results for SS samples confirm that retort processed
DHM is a sterile product (27).
The small sample size is a limitation of our study. However,
clear patterns emerged regarding bioactivity retention during
Holder pasteurization and retort processing. In addition, this
study only looked at 2 of many possible heat-sensitive bioactive
components and our processing and packaging methods may not
reflect the exact methods used by the manufacturer of the SS hu-
man milk product. Additional research on other components in
FIGURE 2 sIgA activity in raw, HP, and SS human milk. Values are means 6 SDs. Bars with different letters are significantly different
(P , 0.001). HP, Holder pasteurized; RAW, raw human milk; sIgA, secretory immunoglobulin A; SS, shelf stable.
FIGURE 3 Lysozyme activity in raw, HP, and SS human milk. Values are means 6 SDs. Bars with different letters are significantly different
(P , 0.001). HP, Holder pasteurized; RAW, raw human milk; SS, shelf stable.
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human milk is needed to provide a more complete understanding
of the impact of retort processing.
Considering the observed differences in bioactivity of lysozyme
and sIgA, a more complete analysis should be performed to deter-
mine the impact of retort processing on all heat-sensitive compo-
nents of human milk, including additional nutrients and bioactive
components. Furthermore, to our knowledge, there is currently no
peer-reviewed literature on health outcomes of medically fragile
infants fed retort processed human milk. Results from this study
are important for clinicians to consider when choosing a feeding
method for any medically fragile or immunocompromised infant.
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